CA2439222A1 - Identification of partial agonists of the a2a adenosine receptor - Google Patents

Identification of partial agonists of the a2a adenosine receptor Download PDF

Info

Publication number
CA2439222A1
CA2439222A1 CA002439222A CA2439222A CA2439222A1 CA 2439222 A1 CA2439222 A1 CA 2439222A1 CA 002439222 A CA002439222 A CA 002439222A CA 2439222 A CA2439222 A CA 2439222A CA 2439222 A1 CA2439222 A1 CA 2439222A1
Authority
CA
Canada
Prior art keywords
identification
adenosine receptor
partial agonists
cvt
partial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002439222A
Other languages
French (fr)
Other versions
CA2439222C (en
Inventor
Luiz Belardinelli
Brent Blackburn
Zhenhai Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Cv Therapeutics, Inc.
Luiz Belardinelli
Brent Blackburn
Zhenhai Gao
Gilead Palo Alto, Inc.
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc., Luiz Belardinelli, Brent Blackburn, Zhenhai Gao, Gilead Palo Alto, Inc., Gilead Sciences, Inc. filed Critical Cv Therapeutics, Inc.
Priority to CA002671940A priority Critical patent/CA2671940A1/en
Publication of CA2439222A1 publication Critical patent/CA2439222A1/en
Application granted granted Critical
Publication of CA2439222C publication Critical patent/CA2439222C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging; in particular, compounds CVT-3033 and CVT-3146 were used.
CA002439222A 2000-02-23 2001-02-23 Identification of partial agonists of the a2a adenosine receptor Expired - Lifetime CA2439222C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002671940A CA2671940A1 (en) 2000-02-23 2001-02-23 Identification of partial agonists of the a2a adenosine receptor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18429600P 2000-02-23 2000-02-23
US60/184,296 2000-02-23
US21987600P 2000-07-21 2000-07-21
US60/219,876 2000-07-21
PCT/US2001/005831 WO2001062979A2 (en) 2000-02-23 2001-02-23 Dentification of partial agonists of the a2a adenosine receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002671940A Division CA2671940A1 (en) 2000-02-23 2001-02-23 Identification of partial agonists of the a2a adenosine receptor

Publications (2)

Publication Number Publication Date
CA2439222A1 true CA2439222A1 (en) 2001-08-30
CA2439222C CA2439222C (en) 2009-07-14

Family

ID=26880004

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002439222A Expired - Lifetime CA2439222C (en) 2000-02-23 2001-02-23 Identification of partial agonists of the a2a adenosine receptor
CA002671940A Abandoned CA2671940A1 (en) 2000-02-23 2001-02-23 Identification of partial agonists of the a2a adenosine receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002671940A Abandoned CA2671940A1 (en) 2000-02-23 2001-02-23 Identification of partial agonists of the a2a adenosine receptor

Country Status (4)

Country Link
US (6) US20020012946A1 (en)
AU (1) AU2001238665A1 (en)
CA (2) CA2439222C (en)
WO (1) WO2001062979A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
DE60227794D1 (en) * 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd NITROGENIC COMPOUND WITH CONDENSED RING AND PYRAZOLYL GROUP AS A SUBSTITUENT AND MEDICAL COMPOSITION THEREOF
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
CA2554169C (en) * 2004-01-27 2010-03-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using adenosine receptor agonists
SG173924A1 (en) * 2004-01-27 2011-09-29 Gilead Palo Alto Inc Myocardial perfusion imaging using adenosine receptor agonists
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
CN101076343A (en) * 2004-10-20 2007-11-21 Cv医药有限公司 Use of A2A adenosine receptor agonists
AU2006204716A1 (en) * 2005-01-12 2006-07-20 King Pharmaceuticals Reserch & Development, Inc. Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
MX2008016254A (en) * 2006-06-22 2009-01-15 Cv Therapeutics Inc Use of a2a adenosine receptor agonists in the treatment of ischemia.
KR20090047499A (en) * 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2011502101A (en) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド Myocardial imaging in patients with a history of lung disease
WO2008086096A2 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
WO2009023179A2 (en) * 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
CA2737077A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
WO2012027379A2 (en) 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
EP3536334B1 (en) 2012-05-16 2021-06-23 Stemline Therapeutics Inc. Cancer stem cell targeted cancer vaccines
US10568483B2 (en) * 2014-12-12 2020-02-25 Irobot Corporation Cleaning system for autonomous robot

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (en) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogous process for the preparation of 2-substituted adenosine derivatives or acid addition salts thereof.
BE787064A (en) 1971-08-03 1973-02-01 Philips Nv MAGNETIC DEVICE CONTAINING DOMAINS
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810946L (en) * 1978-10-20 1980-04-21 Draco Ab METHOD OF TREATING CHRONIC OBSTRUCTIVE AIR DISEASE
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (en) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 2-alkinyladenosine and antihypertensive
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
JPH0638525B2 (en) * 1987-05-06 1994-05-18 株式会社半導体エネルギ−研究所 Method for manufacturing superconducting device
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) * 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (en) 1988-09-15 1990-03-22 Bayer Ag SUBSTITUTED 4-HETEROCYCLYLOXIMINO-PYRAZOLIN-5-ONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL
KR0137786B1 (en) 1988-11-15 1998-05-15 하마구찌 미찌오 Agent for treatment and prophylaxis of ischemic disease of heart or brain
IT1229195B (en) 1989-03-10 1991-07-25 Poli Ind Chimica Spa XANTHINIC DERIVATIVES WITH BRONCODILATORY ACTIVITY AND THEIR THERAPEUTIC APPLICATIONS.
EP0429681B1 (en) 1989-06-20 1995-09-06 Yamasa Shoyu Kabushiki Kaisha (Yamasa Corporation) Intermediate for 2-alkynyladenosine synthesis, production of said intermediate, production of 2-alkynyladenosine from said intermediate, and stable 2-alkynyladenosine derivative
US5032252A (en) 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (en) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg New xanthine derivs. are selective A1 adenosine antagonists - useful for treating CNS disorders (e.g. senile dementia) and heart and circulation disorders
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (en) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med METHOD FOR DESCRIBING ANTIBODY (AB) DIRECTORIES AND T CELL RECEPTORS (TCR) IN THE INDIVIDUAL'S IMMUNE SYSTEM.
JP2740362B2 (en) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 Stable solid 2-octynyl adenosine and process for its preparation
JP3053908B2 (en) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 2-alkynyl adenosine derivatives
JP2916305B2 (en) 1991-07-31 1999-07-05 株式会社タダノ Work machine interlock device
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (en) 1992-04-24 1995-10-11 Gloria Cristalli ADENOSINE DERIVATIVES FOR ACTIVITY A2 AGONIST
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
WO1993025677A1 (en) 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
EP0601322A3 (en) 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosindeaminase inhibitor.
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE69526822T2 (en) * 1994-02-23 2003-01-23 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
WO1998052611A1 (en) 1997-05-23 1998-11-26 Nippon Shinyaku Co., Ltd. Medicinal composition for prevention or treatment of hepatopathy
CA2295195C (en) 1997-06-18 2009-12-15 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU4675699A (en) 1998-06-08 1999-12-30 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
PT1208100E (en) 1999-08-31 2003-07-31 Univ Vanderbilt SELECTIVE ANTAGONISTS OF A2B ADENOSIN RECEPTORS
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
US7109203B2 (en) 2001-05-14 2006-09-19 Novartis Ag Sulfonamide derivatives
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
DK1444233T3 (en) * 2001-11-09 2011-10-17 Gilead Palo Alto Inc A 2B adenosine receptor antagonists
WO2003053366A2 (en) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
WO2003086451A1 (en) * 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
EP1494685B1 (en) 2002-04-18 2008-12-31 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
NZ537975A (en) 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
CA2554169C (en) 2004-01-27 2010-03-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using adenosine receptor agonists
JP2008516969A (en) * 2004-10-15 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Methods of preventing and treating airway remodeling and lung inflammation using A2B adenosine receptor antagonists
CN101076343A (en) * 2004-10-20 2007-11-21 Cv医药有限公司 Use of A2A adenosine receptor agonists
AU2006204716A1 (en) 2005-01-12 2006-07-20 King Pharmaceuticals Reserch & Development, Inc. Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
US7732595B2 (en) * 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US7528617B2 (en) * 2006-03-07 2009-05-05 Testmetrix, Inc. Apparatus having a member to receive a tray(s) that holds semiconductor devices for testing
MX2008016254A (en) 2006-06-22 2009-01-15 Cv Therapeutics Inc Use of a2a adenosine receptor agonists in the treatment of ischemia.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
KR20090047499A (en) 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 Methods and compositions for increasing patient tolerability during myocardial imaging methods
JP2011502101A (en) 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド Myocardial imaging in patients with a history of lung disease
WO2008086096A2 (en) 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
PT2158208E (en) 2007-05-17 2015-06-11 Gilead Sciences Inc Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20100272711A1 (en) 2007-12-12 2010-10-28 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
CA2737077A1 (en) 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods

Also Published As

Publication number Publication date
US8536150B2 (en) 2013-09-17
US8071566B2 (en) 2011-12-06
CA2439222C (en) 2009-07-14
WO2001062979A2 (en) 2001-08-30
US7582617B2 (en) 2009-09-01
CA2671940A1 (en) 2001-08-30
AU2001238665A1 (en) 2001-09-03
US20090317331A1 (en) 2009-12-24
US20150023867A1 (en) 2015-01-22
US9163057B2 (en) 2015-10-20
US20020012946A1 (en) 2002-01-31
US20120251440A1 (en) 2012-10-04
US20050175535A1 (en) 2005-08-11
WO2001062979A3 (en) 2002-02-28
US20040137533A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
CA2439222A1 (en) Identification of partial agonists of the a2a adenosine receptor
CA2397772A1 (en) Method for determining the response to cancer therapy
ZA200100900B (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists.
CA2251453A1 (en) 5-arylalkyl-substituted pyrazolo(4,3-d)pyrimidine-7-ones
CA2270868A1 (en) Method to detect ige
IL138847A0 (en) New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
WO2002047671A3 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
ZA200203293B (en) Method for synthesizing the nucleic acid.
HK1053839A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
FI905589A0 (en) N-SUBSTITUTE DERIVAT AV 3R, 4R-ETHYL - ((1-METHYL-1H-IMIDAZOL-5-YL) METHYL) -2-PYRROLIDINONE.
WO2001009384A3 (en) Serial analysis of genetic alterations
ZA200208346B (en) Polyamide nucleic acid derivatives, agents and methods for producing the same.
WO2002057313A3 (en) Receptor-binding compounds and methods for identifying them
WO2000077518A3 (en) Methods and compositions for opsonophagocytic assays
PT1408035E (en) METHOD FOR THE PREPARATION OF DERIVATIVES OF 1,5-DIARIL-3-TRIFLUOROMETHYL-DELTA2-PYRAZOLINS THAT ARE RACERICALLY AND ENHANCERLY PURE
ZA200303236B (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.
WO2003014324A3 (en) Thermostable uvra and uvrb polipeptides and methods of use
MXPA04003084A (en) Sample carrier with tweezers.
IT1304136B1 (en) COMPOSITION, PROCEDURE AND EQUIPMENT FOR PARTS POLISHING.
PL371913A1 (en) Method for synthesizing beta-l-fluoro-2',3'-dideoxy-didehydcytidine (beta-l-fd4c)
ZA991215B (en) Process for the preparation of 1,3-disubstituted 2-nitroguanidines.
ZA200203532B (en) Method for obtaining nucleic acids from an environment sample, resulting nucleic acids and use in synthesis of novel compounds.
ZA200400055B (en) Method for directly cooling fine-particle solid substances.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210223